Hyperforin . DCHA

Product description: Key constituent of St. John's wort. Shows properties of potential pharmacological interest, including antibacterial [1], anti-malarial [13], anti-inflammatory [7, 14], anti-cancer and anti-angiogenic effects [5, 10]. Anti-depressant and anxiolytic compound [3]. Specific activator of TRPC6 channels [11]. Inhibits the re-uptake of neurotransmitters in synapses (serotonin, norepinephrine, dopamine, GABA, glutamate) [4]. Activator of the pregnane X receptor (PXR) [2]. Regulates expression of the cytochrome P450 CYP3A4 and CYP2C9 and hepatic drugs metabolism [8]. Potential anti-Alzheimer compound [6, 9, 15]. Potent SIRT1 (sirtuin 1) and SIRT2 (sirtuin 2) inhibitor [12]. Based on the anti-inflammatory activity of Hyperforin and its simultaneous blockade of multiple signaling pathways, such as IFN?gamma/IL?1beta/TNF?alpha, JAK/STAT, NF?kappaB and MAPK it has been suggested a valuable agent for cytokine storm treatment during COVID-19 [16].

Alternate Names/Synonyms: (1R,5R,6R,7S)-2-Hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-2-ene-4,9-dione . DCHA

CAS: 238074-03-8

Lien vers la Fiche Technique